At ASCO, AstraZeneca reports strong data for breast cancer drug – STAT
- At ASCO, AstraZeneca reports strong data for breast cancer drug STAT
- Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Nature.com
- ASCO: AstraZeneca, Daiichi’s Enhertu looks to make history again in HER2-ultralow breast cancer FiercePharma
- AstraZeneca’s Enhertu breast cancer trial shows ‘unprecedented’ results The Globe and Mail
- ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer Pharmaceutical Technology
Read More: At ASCO, AstraZeneca reports strong data for breast cancer drug – STAT